Orphan designation: daratumumab Treatment of plasma-cell myeloma, 17/07/2013 Expired
Submitted by Anonymous (not verified) on 4 June 2026 - 14:20
Orphan designation: daratumumab Treatment of plasma-cell myeloma, 17/07/2013 Expired
Human medicines European public assessment report (EPAR): Rapamune, sirolimus, Date of authorisation: 13/03/2001, Revision: 51, Status: Authorised
Submitted by Anonymous (not verified) on 4 June 2026 - 13:50
Human medicines European public assessment report (EPAR): Rapamune, sirolimus, Date of authorisation: 13/03/2001, Revision: 51, Status: Authorised
EMA/PE/0000232781
Submitted by Anonymous (not verified) on 4 June 2026 - 13:38
EMA/PE/0000232781
EMA/PE/0000232771
Submitted by Anonymous (not verified) on 4 June 2026 - 13:38
EMA/PE/0000232771
EMA/PE/0000232769
Submitted by Anonymous (not verified) on 4 June 2026 - 13:38
EMA/PE/0000232769
Human medicines European public assessment report (EPAR): Enflonsia, clesrovimab, Date of authorisation: 15/04/2026, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 4 June 2026 - 13:38
Human medicines European public assessment report (EPAR): Enflonsia, clesrovimab, Date of authorisation: 15/04/2026, Revision: 1, Status: Authorised
EMA/PE/0000232764
Submitted by Anonymous (not verified) on 4 June 2026 - 13:35
EMA/PE/0000232764
EMA/PE/0000232763
Submitted by Anonymous (not verified) on 4 June 2026 - 12:48
EMA/PE/0000232763
EMA/PE/0000232638
Submitted by Anonymous (not verified) on 4 June 2026 - 12:48
EMA/PE/0000232638
EMA/PE/0000232759
Submitted by Anonymous (not verified) on 4 June 2026 - 12:48
EMA/PE/0000232759